A similar report from the CALGB group that included 48 patients with inv(16)/t(16;16) AML under 60 years showed also a significantly lower 5-year relapse rate with 3 or 4 cycles of HDAC (n = 28) compared with one course of HDAC (n = 20) in consolidation [30]. Here, HDAC9 is linked to acute myeloid leukemia.